Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Exelixis Inc (NQ: EXEL ) 22.60 +0.04 (+0.18%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,351,379 Open 22.57 Bid (Size) 22.58 (71) Ask (Size) 22.59 (5) Prev. Close 22.56 Today's Range 22.53 - 22.75 52wk Range 18.64 - 24.34 Shares Outstanding 315,048,788 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals. July 18, 2024 EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying. Via Chartmill 7 Cheap Biotech Stocks With Major Upside Potential July 09, 2024 While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks. Via InvestorPlace Performance YTD -5.56% -5.56% 1 Month +4.00% +4.00% 3 Month -1.18% -1.18% 6 Month -0.18% -0.18% 1 Year +14.78% +14.78% More News Read More When you look at NASDAQ:EXEL, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. June 27, 2024 Via Chartmill Don't overlook NASDAQ:EXEL—it's a hidden gem with strong fundamentals and an attractive price tag. June 06, 2024 Via Chartmill 10 Health Care Stocks Whale Activity In Today's Session May 31, 2024 Via Benzinga The Analyst Verdict: Exelixis In The Eyes Of 5 Experts May 01, 2024 Via Benzinga Technical Signals Point to a Possible Breakout for EXELIXIS INC. April 24, 2024 Via Chartmill What Analysts Are Saying About Exelixis Stock April 10, 2024 Via Benzinga Over $8M Bet On This Health Care Stock? Check Out These 4 Stocks Insiders Are Buying May 31, 2024 Via Benzinga Exelixis to Present at the William Blair 44th Annual Growth Stock Conference May 28, 2024 From Exelixis, Inc. Via Business Wire Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA May 20, 2024 From Exelixis, Inc. Via Business Wire In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals. May 15, 2024 Via Chartmill Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You? May 12, 2024 Via The Motley Fool MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths' May 10, 2024 Via Benzinga Just Say No to Drugs: 3 Pharma Stocks to Avoid May 08, 2024 Via InvestorPlace Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May May 07, 2024 From Exelixis, Inc. Via Business Wire Exelixis (EXEL) Q1 2024 Earnings Call Transcript May 01, 2024 Via The Motley Fool Topics Earnings Exposures Financial EXEL Stock Earnings: Exelixis Misses EPS, Misses Revenue for Q1 2024 April 30, 2024 Via InvestorPlace Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update April 30, 2024 From Exelixis, Inc. Via Business Wire The Top 3 Biotech Stocks to Buy in April 2024 April 27, 2024 Via InvestorPlace NASDAQ:EXEL is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. April 24, 2024 Via Chartmill Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024 April 16, 2024 From Exelixis, Inc. Via Business Wire NASDAQ:EXEL is an undervalued gem with solid fundamentals. March 29, 2024 Via Chartmill 3 Biotech Stocks to Buy on the Dip: March 2024 March 27, 2024 Via InvestorPlace 4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market March 23, 2024 Via The Motley Fool Topics Stocks Exposures US Equities Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
